Alterations in the tumour suppressor p53 gene are among the most common defects seen in a variety of human cancers. In order to study the significance of the p53 gene in the genesis and development of human glioma from Indian patients, we checked 44 untreated primary gliomas for mutations in exons 5-9 of the p53 gene by PCR-SSCP and DNA sequencing. Sequencing analysis revealed six missense mutations. The incidence of p53 mutations was 13⋅6% (6 of 44). All the six mutations were found to be located in the central core domain of p53, which carries the sequence-specific DNA-binding domain. These results suggest a rather low incidence but a definite involvement of p53 mutations in the gliomas of Indian patients.
Introduction
Glioma, a neoplasm of neuroglial cells, is the most common type of brain tumour, constituting more than 50% of all brain tumours. Gliomas account for about 2% of the malignant tumours in adults. Malignant gliomas are the leading cause of central nervous system (CNS) tumourrelated death. Patients with glioblastoma have a life expectancy of less than one year even after surgery, chemo-and radiotherapy (Burger and Scheithauer 1993) . The prognosis is even worse in children with brain stem malignant gliomas, the death occurring within 6-12 months after diagnosis (Epstein and McCleary 1986) . A better understanding of the biological pathway leading to glial tumourigenesis is essential to arrive at new therapeutic modalities.
The p53 tumour suppressor gene is the most frequently altered gene in human cancer, including brain tumours. The p53 protein is a transcription factor involved in maintaining genomic integrity by controlling cell cycle progression and cell survival (Levine 1997; Somasundaram and El-Deiry 2000) . Consistent with this view, about 50% of primary human tumours carry mutations in the p53 gene (Hollstein et al 1991; Levine et al 1991) . The function of p53 is critical to the efficiency of many cancer treatment procedures, because radiotherapy and chemotherapy act in part by triggering programmed cell death in response to DNA damage. Consequently, tumours which carry mutations in p53 are often difficult to treat, and their prognosis is poor. The characterization of the biochemical pathways by which p53 alteration triggers tumourigenesis is the foundation for the design of novel therapeutic approaches.
Karyotype analysis and restriction fragment length polymorphism (RFLP) analysis of glioma have shown several numerical and structural alterations of chromosomes (Bigner et al 1988; Libermann et al 1985; James et al 1988; Fujimoto et al 1989) . One of the alterations frequently seen in glioma is LOH on chromosome 17p, which leads to deletion of the region that includes p53 (Chung et al 1991; Frankel et al 1992; Fults et al 1992; von Deimling et al 1992; Ghosh et al 1994; Rasheed et al 1994; Jain et al 1999) . Studies at many laboratories have shown that approximately 25% of the glioma carries mutations in p53 gene (Nigro et al 1989; Chung et al 1991; Mashiyama et al 1991; Ohgaki et al 1991; Frankel et al 1992; Fults et al 1992; Saxena et al 1992; von Deimling et al 1992; Louis et al 1993) .
In the study reported here, we tested 44 glioma samples from Indian patients for mutations in the p53 tumour suppressor gene by PCR-SSCP method. We found the p53 gene mutated in 13⋅6% (6/44) of the gliomas.
Materials and methods

Tumour samples
Glioma tissue samples were obtained from patients who underwent surgery at Manipal Hospital, Bangalore, India. Forty-four patients with different grades of glioma were chosen for the study. Tissue samples were kept frozen at -70°C. Total DNA was isolated from a part of the frozen samples. Tissue sections were used to identify the histopathological grade and the type of glioma.
Isolation of DNA
A commercial DNA isolation kit (Qiagen, USA) was used to isolate genomic DNA from 25 mg of glioma tissue.
Primers for PCR and DNA sequencing
The primers used were oligonucleotides complementary to the sequence flanking the exon/intron junctions of exons 5-9 (Kovach et al 1991) . The sequence of the primers is as follows: exon 5, 5′-CTGACTTTCAACTCTG-3′ (forward) and 5′-AGCCCTGTCGTCTCT-3′ (reverse); exon 6, 5′-CTCTGATTCCTCACTG-3′ (forward) and 5′-ACCCCA GTTGCAAACC-3′ (reverse); exon 7, 5′-TGCTTGCCACA GGTCT-3′ (forward) and 5′-ACAGCAGGCCAGTGT-3′ (reverse); exon 8, 5′-AGGACCTGATTTCCTTAC-3′ (forward) and 5′-TCTGAGGCATAACTGC-3′ (reverse); exon 9, 5′-TATGCCTCAGATTCACT-3′ (forward) and 5′-ACTTGATAAGAGGTCC-3′ (reverse). The same sets of primers were used for DNA sequencing.
Polymerase chain reaction
Genomic DNA (100 ng) was used for amplification in 25 µl of reaction mixture. The composition of the 10X buffer used for all exons (except exon 7) was: 100 mM Tris-HCl (pH 9⋅0), 15 mM MgCl 2 , 500 mM KCl, 0⋅1% gelatin. For exon 7, the composition was: 100 mM TrisHCl (pH 8⋅3), 35 mM MgCl 2 , 250 mM KCl. Each PCR reaction had a 1X PCR buffer, 100 µM dNTPs (Gibco BRL), 5 µCi α[ 32 P]dATP, 5 pmol of each primer (Microsynth) and 0⋅5 U of Taq DNA polymerase (Bangalore Genei). PCR conditions for exon 5, 6 and 8 were 94°C for 5 min, 30 cycles of 94°C for 1 min, 57°C for 1 min and 72°C for 30 s and a final cycle of 72°C for 10 min. The condition for exon 7 was 94°C for 5 min, 30 cycles of 94°C for 1 min, 65°C for 1 min and 72°C for 10 s, and a final cycle of 72°C for 10 min. The condition for exon 9 was 94°C for 5 min, 30 cycles of 94°C for 1 min, 56°C for 1 min and 72°C for 15 s, and a final cycle of 72°C for 10 min.
Single strand conformation polymorphism analysis
Labelled PCR products were checked for amplification by 2% agarose gel electrophoresis, diluted to 10 to 100-fold in a loading and denaturing buffer (95% formamide, 0⋅25% bromophenol blue, 0⋅25 xylene cyanol, 10 mM EDTA, pH 8⋅0 and 0⋅1 N NaOH), heated at 85°C for 5 min and then subjected to single strand conformation polymorphism (SSCP) analysis using 6% non-denaturing polyacrylamide gel with 5% glycerol and 0⋅5X TBE as running buffer. Electrophoresis was carried out at 500 V for 3⋅5 h at 22°C for exons 5, 6, 7 and 9. For exon 8, the conditions remained the same, except that the gel was run at 15°C. Samples that showed band shifts were chosen for further study.
Direct DNA sequencing
Bands showing abnormal shifts in the SSCP analysis were purified from acrylamide gel using Microcon spin columns (Millipore) and used as templates to reamplify the fragment with the same set of primers originally used for amplification. The amplified DNA fragments were purified with a QIAquick PCR purification kit (Qiagen) and subjected to cycle sequencing (fmol cycle sequencing kit; Promega) in both directions. Sequencing reactions were carried out in a thermal cycler under the following cycling conditions: 95°C for 2 min, 30 cycles of 95°C for 30 s, 42°C for 30 s, and 70°C for 1 min. The samples were electrophoresed on a 6% polyacrylamide denaturing gel. Gels were dried under vacuum at 80°C, and exposed for Phosphor Imaging.
Results
PCR-SSCP analysis for detection of mutations
PCR fragments generated from exons 5 to 9 of the p53 gene were subjected to SSCP analysis. All 44 glioma samples were checked for mutations. DNA samples showing mobility shifts or abnormal bands were scored as positive for mutation. Of the 44 samples analysed, six tumour DNAs showed an altered pattern in PCR-SSCP analysis ( figure 1; table 1 ). Exon 5 analysis revealed the presence of mutation in samples G2 (figure 1a), G10 (data not shown) and G20 ( figure 1b) . Sample 34 showed a differentially migrating band in exon 7 (figure 1c). Samples G23 and G33 (figure 1d) showed additional bands in exon 8 moving differently from normal bands.
Identification of mutations by sequence analysis
The bands that showed abnormal shifts in all the samples mentioned above were purified from gel and subjected to DNA sequencing. The sequencing revealed the presence of mutation in all the six samples. Figure 2 shows the results of sequencing of some of the samples. Exon 5 of samples G2 and G10 had the same missense mutation (G-T), resulting in the conversion of valine to phenylalanine at codon 172 (figure 2a). Exon 5 of sample G20 had the missense mutation (T-G), resulting in the conversion of valine to glycine at codon 173 (data not shown). Exon 7 of sample G34 showed the missense mutation (T-G), which converted leucine to arginine at codon 257 (data not shown). Exon 8 of G23 had the missense mutation (C-T), which caused the conversion of arginine to cysteine at codon 273 (figure 2b). G33 had the missense mutation (T-G) in exon 8, which resulted in the conversion of phenylalanine to cysteine at codon 270 (figure 2c).
Discussion
The most frequent chromosomal abnormalities associated with glioma are gains of chromosome 7, losses of 10, 9p and 17p and EGFR gene amplification (Libermann et al 1985; Bigner et al 1988; James et al 1988; Fujimoto et al 1989) . The loss of 17p is usually associated with mutations in the p53 gene (Chung et al 1991; Frankel et al 1992; Fults et al 1992; von Deimling et al 1992; Ghosh et al 1994; Jain et al 1999) . The involvement of p53 in the development of glioma from Indian patients has been shown by loss of heterozygosity (LOH) analysis (Chattopadhyay et al 1997; Gosh et al 1994) . The present study was carried out to determine the frequency of p53 mutation in glioma derived from the Indian population. We analysed 44 glioma samples to check for mutations in exons 5-9 of p53 gene by the PCR-SSCP method. We found that 13⋅6% of the tumours tested positive for p53 mutations (table 1) . To our knowledge, ours is the first study of p53 mutation in glioma from the Indian population.
The central core of p53, which spans from amino acids 100 to 300, contains the sequence-specific DNA-binding domain. This is the domain where majority of p53 mutations have been found to occur. In our study, all six mutations were mapped to this domain.
The occurrence of p53 mutations in glioma has generally been associated with age. While the p53 alterations are rare among pediatric age groups, their incidence is high in young adults, and low among the older age group (Louis et al 1993; Rasheed et al 1994) . This study shows that the incidence of p53 mutations amongst young adults (19-50 years) is 18% (5/27) and amongst patients > 50 years old is 6⋅7% (1/15). No mutations of the p53 gene among the pediatric age group could be detected (0/2). 
*DBD refers to DNA binding domain of p53; **GBM refers to glioblastoma multiforme.
About 83% of the mutations were found in young adults (5/6), while only 17% were found in the older group (1/6). Thus our results confirm the relationship between p53 mutation and the age of the patient, as shown previously by others. Mutations of p53 were detected both in low-grade (grade II) and high-grade (grade III, IV) gliomas, with frequencies varying between 25 and 35% (Ohgaki et al 1995) . Our results show that the p53 mutation frequency is higher in low-grade gliomas than in high-grade gliomas. Grade II gliomas, which mainly comprise astrocytomas, had a frequency of 25% (3/12), while grade III gliomas, which are mainly anaplastic astrocytomas, had a frequency of 15⋅4% (2/13). In contrast to this, the p53 mutation occurred at a low frequency of 5⋅4% (1/19) among grade IV glioblastoma multiforme cases. Three of the six p53 mutations were found in grade II gliomas.
Other mechanisms implicated in the abnormal functioning of p53 are the amplification of MDM2 gene and the inactivation of p14 ARF gene product. The binding of MDM2 protein to p53 results not only in the inhibition of p53-mediated transcription, but also in the rapid degradation of p53 (Oliner et al 1993; Haupt et al 1997; Kubbutat et al 1997) . The binding of p14 ARF to the MDM2 protein inhibits the MDM2-mediated degradation of p53 (Kamijo et al 1998; Stott et al 1998; Zhang et al 1998; Orlow et al 1999) . Studies of the status of MDM2 and p14 ARF genes in these glioma samples are currently in progress. 
